No Data
No Data
CMB International: bullish on the rebound of Mainland China's pharmaceutical industry, with continued bullish policy implementation.
Zhaojin International continues to be bullish on Shenzhen Mindray Bio-Medical Electronics, United Imaging Medical, Innovent Bio (01801), Beigene (06160), Genscript Biotech (02273), Kelun Pharma (06990), and Anpac Bio-Medical Science (02367).
Express News | Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients With Type 2 Diabetes Met Study Endpoints, and Plans to Submit Nda of Mazdutide to the Nmpa
Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients With Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
SAN FRANCISCO and SUZHOU, China, July 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and
China Securities Co.,Ltd: Accelerating development of the self-immunity market to promote the improvement and efficiency of the domestic innovative drug industry.
The patient population with autoimmune diseases and type II inflammation is growing rapidly, the market size is second only to cancer drugs, but still in a period of accelerated development. Existing drugs still have huge room for improvement in efficacy and safety.
Nomura Adjusts Innovent Biologics' Price Target to HK$55.87 From HK$55.31, Keeps at Buy
Nomura: Maintains a "buy" rating for Innovent Bio (01801), with a target price raised to HKD 55.87.
Nomura raised its sales forecast for Innovent Bio's core product Tyvyt, a PD-1 antibody for lung cancer, to RMB 3.2 billion and RMB 3.4 billion in 2021 and 2022 respectively.
No Data